Annual Financials for Rockwell Medical Inc.
Fiscal year is January-December. All values USD millions. |
2015 | 2016 | 2017 | 2018 | 2019 |
5-year trend |
Sales/Revenue
|
55.35M | 53.28M | 57.3M | 63.39M | 61.3M | |
Sales Growth |
- | -3.73% | 7.54% | 10.63% | -3.29% | |
Cost of Goods Sold (COGS) incl. D&A |
46.41M | 46.53M | 53.6M | 64.97M | 58.46M | |
COGS excluding D&A |
45.59M | 45.77M | 53.08M | 64.32M | 55.81M | |
Depreciation & Amortization Expense |
822,294 | 762,368 | 514,362 | 650,142 | 2.65M | |
Depreciation |
655,265 | 601,093 | 514,009 | 649,789 | 2.65M | |
Amortization of Intangibles |
167,029 | 161,275 | 353 | 353 | 353 | |
COGS Growth |
- | 0.26% | 15.19% | 21.22% | -10.02% | |
Gross Income |
8.94M | 6.75M | 3.7M | (1.58M) | 2.84M | |
Gross Income Growth |
- | -24.45% | -45.18% | -142.80% | 279.17% | |
Gross Profit Margin |
- | - | - | - | 4.63% | NA |
|
2015 | 2016 | 2017 | 2018 | 2019 |
5-year trend |
SG&A Expense |
24.04M | 26.96M | 29.62M | 29.82M | 36.93M | |
Research & Development |
4.96M | 5.84M | 6.32M | 6.74M | 6.89M | |
Other SG&A |
19.08M | 21.12M | 23.3M | 23.08M | 30.05M | |
SGA Growth |
- | 12.15% | 9.88% | 0.67% | 23.84% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | - | 1.03M | 430,000 | |
EBIT after Unusual Expense |
- | - | - | (32.44M) | (34.53M) | |
Non Operating Income/Expense |
- | - | (788,590) | (222,020) | 30,180 | |
Non-Operating Interest Income |
681,876 | 810,340 | 790,226 | 535,328 | 367,077 | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | - | - | - | |
Interest Expense Growth |
- | - | - | - | - | |
Gross Interest Expense |
- | - | - | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(14.42M) | (19.4M) | (25.92M) | (32.13M) | (34.13M) | |
Pretax Income Growth |
- | -34.52% | -33.63% | -23.94% | -6.23% | |
Pretax Margin |
- | - | - | - | -55.67% | NA |
Income Tax |
- | 404,527 | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(14.42M) | (19.8M) | (25.92M) | (32.13M) | (34.13M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(14.42M) | (19.8M) | (25.92M) | (32.13M) | (34.13M) | |
Net Income Growth |
- | -37.33% | -30.90% | -23.94% | -6.23% | |
Net Margin Growth |
- | - | - | - | -55.67% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(14.42M) | (19.8M) | (25.92M) | (32.13M) | (34.13M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(14.42M) | (19.8M) | (25.92M) | (32.13M) | (34.13M) | |
EPS (Basic) |
(0.29) | (0.39) | (0.51) | (0.61) | (0.56) | |
EPS (Basic) Growth |
- | -34.48% | -30.15% | -19.82% | 7.89% | |
Basic Shares Outstanding |
50.07M | 50.68M | 51.07M | 52.82M | 60.92M | |
EPS (Diluted) |
(0.29) | (0.39) | (0.51) | (0.61) | (0.56) | |
EPS (Diluted) Growth |
- | -34.48% | -30.15% | -19.82% | 7.89% | |
Diluted Shares Outstanding |
50.07M | 50.68M | 51.07M | 52.82M | 60.92M | |
EBITDA |
(14.28M) | (19.45M) | (25.41M) | (30.76M) | (31.44M) | |
EBITDA Growth |
- | -36.18% | -30.66% | -21.06% | -2.22% | |
EBITDA Margin |
- | - | - | - | -51.29% | NA |